Enanta is committed to developing new treatments for viral infections and liver diseases. Enanta has active research and development programs in areas such as respiratory syncytial virus (RSV), non-alcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), hepatitis B virus (HBV), and human metapneumovirus (hMPV).

If you are a healthcare professional interested in learning more about Enanta’s clinical trials, please contact: Nathalie Adda, MD at

Learn more about any of our clinical trials described below by clicking the identifier listed below the description of the trial.

Non-Alcoholic Steatohepatitis

A Phase 2b Randomized, Double Blind, Placebo-Controlled, Multicenter Study Evaluating Safety and Efficacy of EDP-305 in Subjects With Liver Biopsy Proven Non-Alcoholic Steatohepatitis (NASH) (ARGON-2) identifier: NCT04378010

A Randomized, Double-Blind, Placebo-Controlled, First-In-Human Study of Orally Administered EDP-297 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses (SAD), Multiple Ascending Doses (MAD), and the Effect of Food on EDP-297 Pharmacokinetics in Healthy Subjects Identifier: NCT04559126

Respiratory Syncytial Virus

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study of EDP-938 Administered Orally for the Treatment of Acute Upper Respiratory Tract Infection With Respiratory Syncytial Virus in Ambulatory Adult Subjects (RSVP) identifier: NCT04196101

Hepatitis B Virus

A study of EDP-514 in Healthy Subjects (Part 1) and Patients with Chronic Hepatitis B Virus Infection (Part 2) identifier: NCT04008004

A Study of EDP-514 in Patients With Chronic Hepatitis B Virus Infection Who Are Not Currently on Treatment Identifier: NCT04470388